A young university student whose repeated symptoms of stomachache, nausea, vomiting, and weight loss were dismissed by ...

Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera Pharmaceuticals, LLC for QINLOCK® (ripretinib), which ...

Gastrointestinal stromal tumors (GIST) are rare mesenchymal tumors and were among the first solid tumor types for which such a novel treatment (in this case imatinib) became available.

Gastrointestinal stromal tumors, or GISTs, may be rare but in the world of digestive system tumors, they’re the most common of their kind.

Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours ...

Last year, Ono acquired Deciphera in a $2.4 billion deal. In addition to Romvimza, Ono gained Qinlock, a cancer drug that Deciphera steered to a 2020 FDA approval in gastrointestinal stromal tumor.

Abbreviations GIST: Gastrointestinal stromal tumor; NIH: National Institutes of Health; IM: Imatinib mesylate; OS: Overall survival; RFS: Relapse-free survival; GI: Gastrointestinal; ICC ...

Most advanced gastrointestinal stromal tumors (GISTs) start with cancer-causing cell changes, or mutations, in specific genes. Changes in proteins called KIT and PDGFRA most commonly cause this ...

Disease Course and Treatment Outcomes in Patients With De Novo Small-Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 20 Insertion: Two Case Reports Supported by Grant-in-Aid for Rare Cancer ...

GISTs are mesenchymal tumors that are considered to originate from the intestinal cells of Cajal or their progenitor cells. About 70%-80% of GISTs are caused by mutations in KIT 7, 8 and approximately ...

Gastrointestinal stromal tumors (GISTs) Gastrointestinal stromal tumors (GISTs) occur when a special type of nerve cell in your stomach lining and walls becomes cancerous.